ADDRESSES
Head office
9 Balogun street
Off Kudirat Abiola way
Central Business District
Alausa,
Ikeja, Lagos
Nigeria.
REGIONAL OFFICE
2nd floor, Dbm plaza,
Plot 1381-1383, Aminu Kano, crescent, Wuse II, Abuja.
Nigeria
Work Hours
Monday to Friday: 8AM - 5PM
Enzyme ImmunoAssay (ELISA) for the determination of IgM antibodies to Chlamydia Pneumoniae in human plasma and sera. The product is intended for the follow-up of patients showing respiratory pathologies referable to Chl. pneumoniae infection
Micro-plates are coated with a preparation of native C.pneumoniae. In the 1st incubation, the solid phase is treated with diluted samples and anti-C.pneumoniae IgM are captured, if present, by the solid phase.After washing out all the other components of the sample, in the 2nd incubation bound anti-CP IgM are detected by the addition of anti hIgM antibody, labeled with peroxidase (HRP). The enzyme captured on the solid phase, acting on the substrate/chromogen mixture, generates an optical signal that is proportional to the amount of anti-CP IgM antibodies present in the sample. The presence of IgM in the sample may therefore be determined by means of a cut-off value able to discriminate between negative and positive samples.Neutralization of IgG anti-CP, carried out directly in the well, is performed in the assay in order to block interferences due to this class of antibodies in the determination of IgM.
Enzyme ImmunoAssay (ELISA) for the qualitative determination of IgA antibodies to Chlamydia Trachomatis in human plasma and sera. The product is intended for the follow-up of patients showing pathologies referable to Chl. Trachomatis infection.
For “in vitro” diagnostic use only.
Microplates are coated with a species-specific polypeptide derived from C.trachomatis major outer membrane antigen.
In the 1st incubation, the solid phase is treated with diluted samples and anti-C.trachomatis IgA are captured, if present, by the antigens.
After washing out all the other components of the sample, in the 2nd incubation bound anti-C.trachomatis IgA are detected by the addition of anti hIgA antibody, labelled with peroxidase (HRP).
Enzyme ImmunoAssay (ELISA) for the quantitative determination of IgG antibodies specific to Chlamydia trachomatis in human plasma and sera.
The kit is intended for the follow up of patients undergoing a Chlamydia trachomatis infection.
For in vitro diagnostic use only. Microplates are coated with an immunodominant species-specific polypeptide derived from Chlamydia trachomatis major outer-membrane antigen (MOMP), that makes the assay very specific for C.trachomatis (no cross reaction with C.pneumoniae).
In the 1st incubation, the solid phase is treated with diluted samples and anti-C.trachomatis IgG are captured, if present, by the solid phase.
After washing out all the other components of the sample, in the 2nd incubation bound anti-C.trachomatis IgG are detected by the addition of anti hIgG antibody, labelled with peroxidase (HRP).
The enzyme captured on the solid phase, acting on the substrate/chromogen mixture, generates an optical signal that is proportional to the amount of anti-C.trachomatis IgG antibodies present in the sample. IgG in the sample may be quantitated by means of a standard curve calibrated in arbitrary units per milliliter (Uarb/ml) as no international standard is available.
Microplates are coated with purified Treponema pallidum synthetic antigens (p15, p17 and p47). Patient’s serum/plasma is added to the microwell together with a mix of Tp synthetic antigens, labelled with peroxidase (HRP).
The specific immunocomplex, formed in the presence of anti Tp Ab in the sample, is captured by the solid phase.
At the end of the one-step incubation, microwells are washed to remove unbound serum proteins and HRP conjugate. The chromogen/substrate is then added and, in the presence of captured immunocomplex, the colorless substrate is hydrolyzed by the bound HRP conjugate to a colored end-product.
After blocking the enzymatic reaction, its optical density is measured by an ELISA reader. The color intensity is proportional to the amount of anti Tp Ab present in the sample. The version ULTRA is suitable for automated screenings
Enzyme ImmunoAssay (ELISA) for the quantitative determination of IgG antibodies to Tetanus toxoid in human serum and plasma.
Tetanus is caused by an infection with the bacterium Clostridium tetani which is commonly found in soil, dust and manure. Tetanus occurs in all parts of the world but is most frequent in hot and wet climates where the soil contains a lot of organic matter. The bacteria generally enter through a break in the skin such as a cut or puncture wound by a contaminated object. They produce toxins that interfere with muscle contractions, resulting in the typical symptoms. Diagnosis is based on the presenting signs and symptoms. The disease does not spread between people. Infection can be prevented by proper immunization with the inactivated tetanus toxoid vaccine. In those who have a significant wound and less than three doses of the vaccine both immunization and tetanus immune globulin are recommended. In those who are infected tetanus immune globulin or, if it is not available, intravenous immunoglobulin (IVIG) is used.
The determination of IgG to the Tetanus Toxin is quite important for the decision to proceed or not in active or passive vaccination.
Enzyme ImmunoAssay (ELISA) for the determination of IgM antibodies to Chlamydia Trachomatisin human plasma and sera.
For “in vitro” diagnostic use only.
The determination of species-specific IgG, IgM and IgA is a helpful tool for the clinician to identify the infective agent and to decide the right therapy. The kit is intended for the follow up of patients undergoing a Chlamydia trachomatis infection. Microplates are coated with a species-specific polypeptide derived from C.trachomatis major outer membrane antigen.
In the 1st incubation, the solid phase is treated with diluted samples and anti-CT IgM are captured, if present, by the antigens.
After washing out all the other components of the sample, in the 2nd incubation bound anti-CT IgM are detected by the addition of anti hIgM antibody, labeled with peroxidase (HRP).
The enzyme captured on the solid phase, acting on the substrate/chromogen mixture, generates an optical signal that is proportional to the amount of anti-CT IgM antibodies present in the sample.
The presence of IgM in the sample may therefore be determined by means of a cut-off value able to discriminate between negative and positive samples.
Neutralization of IgG anti-CT, carried out directly in the well, is performed in the assay in order to block interferences due to this class of antibodies in the determination of IgM
Enzyme ImmunoAssay (ELISA) for the quantitative determination of IgG antibodies to Chlamydia pneumoniae in human plasma and sera. The kit is intended for the follow up of patients undergoing a Chlamydia pneumoniae infection.
Micro-plates are coated with a preparation of native C.pneumoniae. In the 1st incubation, the solid phase is treated with diluted samples and anti-C.pneumoniae IgG are captured, if present, by the solid phase.After washing out all the other components of the sample, in the 2nd incubation bound anti-C.pneumoniae IgG are detected by the addition of anti hIgG antibody, labeled with peroxidase (HRP). The enzyme captured on the solid phase, acting on the substrate/chromogen mixture, generates an optical signal that is proportional to the amount of anti-C.pneumoniae IgG antibodies present in the sample. IgG in the sample may be quantitated by means of a standard curve calibrated in arbitrary units per milliliter (Uarb/ml) as no international standard is available.
Enzyme ImmunoAssay (ELISA) for the determination of IgM antibodies to Treponema pallidum (Tp) in human plasma and sera. The kit is intended for the follow-up of Tp-infected patients. For “in vitro” diagnostic use only.
Microplates are coated with Tp immunodominant synthetic antigens (recombinant p47, p17 and TmpA).In the 1st incubation, the solid phase is treated with diluted samples and anti-Tp IgM are captured, if present, by the antigens.
After washing out all the other components of the sample, in the 2nd incubation bound anti-Tp IgM are detected by the addition of anti hIgM antibody, labeled with peroxidase (HRP). The enzyme captured on the solid phase, acting on the substrate/chromogen mixture, generates an optical signal that is proportional to the amount of anti-Tp IgM antibodies present in the sample.
The presence of IgM in the sample may therefore be determined by means of a cut-off value able to discriminate between negative and positive samples.
Neutralization of IgG anti-Tp, carried out directly in the well, is performed in the assay in order to block interferences due to this class of antibodies in the determination of IgM.
Enzyme ImmunoAssay (ELISA) for the determination of IgG antibodies to groups ACWY Meningococcus in human plasma and sera.
The product is intended for the follow-up of patients administered with a meningococcal vaccine, containing the polysaccharides from groups A, C, Y and W135. Micro-plates are coated with a preparation of purified capsular polysaccharides formed by serogroups A, B, C, Y and W135. In the 1st incubation, the solid phase is treated with diluted samples and anti-Meningococcus IgG are captured, if present, by the antigens.After washing out all the other components of the sample, in the 2nd incubation bound anti-Men IgG are detected by the addition of anti hIgG antibody, labeled with peroxidase (HRP). The enzyme captured on the solid phase, acting on the substrate/chromogen mixture, generates an optical signal that is proportional to the amount of anti-Men IgG antibodies present in the sample. A cut-off value permits to transform the optical density values detected in positive or negative results due to the presence of absence of anti-Men IgG.
